股本结构
单位：万股
| 公告日期 | 2026-10-05 | 2026-10-02 | 2026-08-21 | 2026-08-14 | 2026-08-14 | 2026-05-18 |
|---|---|---|---|---|---|---|
| 证券总股本 | 210.20 | 2101.99 | 1897.20 | 1439.19 | 360.95 | 269.25 |
| 普通股本 | 210.20 | 2101.99 | 1897.20 | 1439.19 | 360.95 | 269.25 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 2.78 | 1.46 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-05 | 2026-10-02 | 2026-08-18 | 2026-08-10 | 2026-06-30 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-05 | 210.20 | 未披露 |
更多>>
a 1-for-10 reverse split ratio of common stock
|
2026-10-05 |
| 2026-10-02 | 2101.99 | 未披露 | 定期报告 | 2026-10-02 |
| 2026-08-21 | 1897.20 | 未披露 | 定期报告 | 2026-08-18 |
| 2026-08-14 | 1439.19 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-08-14 | 360.95 | 2.78 |
更多>>
From March 31, 2026 to June 30, 2026
Conversion of preferred stock
|
2026-06-30 |
| 2026-05-18 | 269.25 | 1.46 |
更多>>
From December 31, 2025 to March 31, 2026
Conversion of preferred stock
Issuance of common stock and other equity-classified contracts
Issuance of common stock upon exercise of warrants
|
2026-03-31 |
| 2026-03-31 | 269.25 | 未披露 | 定期报告 | 2026-03-20 |
| 2026-03-23 | 235.71 | 1.52 | 定期报告 | 2026-03-09 |
| 2026-02-06 | 206.10 | 未披露 |
更多>>
Common Stock offered 392,608 shares by the company
|
2026-02-06 |
| 2026-03-31 | 173.90 | 1.17 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock for asset acquisitions
Issuance of common stock upon release of Prepaid Series Warrants
Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs
Issuance of common stock upon the ATM Offering, net of issuance costs
Issuance of Series J Convertible Preferred Stock in exchange for royalties payable due to related parties, net of issuance costs
Conversion of convertible preferred stock
|
2025-12-31 |
| 2025-11-13 | 166.84 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-13 | 164.71 | 1.49 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock upon the ATM Offering, net of issuance costs
|
2025-09-30 |
| 2025-09-15 | 148.73 | 1.49 | 定期报告 | 2025-09-10 |
| 2025-07-28 | 120.00 | 未披露 |
更多>>
a 1-for-19 reverse split ratio of common stock
|
2025-08-15 |
| 2025-08-11 | 2332.75 | 未披露 | 定期报告 | 2025-08-04 |
| 2025-07-28 | 2330.00 | 未披露 | 定期报告 | 2025-07-28 |
| 2025-08-11 | 1886.16 | 1.49 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs
Conversion of preferred stock
Issuance of common stock upon the ATM Offering, net of issuance costs
Issuance of common stock upon release of Prepaid Series Warrants
Issuance of common stock for asset acquisition
Issuance of common stock for vested restricted stock awards
|
2025-06-30 |
| 2025-06-09 | 1259.39 | 未披露 | 定期报告 | 2025-06-05 |
| 2025-05-14 | 1101.73 | 未披露 | 定期报告 | 2025-05-05 |
| 2025-05-14 | 926.86 | 1.27 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock for asset acquisition
Issuance of common stock upon release of Prepaid Series Warrants
|
2025-03-31 |
| 2025-03-31 | 926.86 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-03-31 | 800.46 | 1.27 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock upon exercise of Pre-Funded Warrants
Issuance of common stock upon exercise of Series Warrants
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs
Issuance of common stock through October 2024 Warrant Inducement Offer, net of issuance costs
Conversion of Series A Convertible Preferred Stock
|
2024-12-31 |
| 2024-11-25 | 800.46 | 1.27 | 定期报告 | 2024-11-18 |
| 2024-10-30 | 800.46 | 未披露 | 定期报告 | 2024-10-29 |
| 2024-11-14 | 345.27 | 1.27 |
更多>>
From June 30, 2024 to September 30, 2024
Conversion of Series A Convertible Preferred Stock
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs
Issuance of common stock upon exercise of Pre-Funded Warrants
|
2024-09-30 |
| 2024-09-09 | 280.42 | 未披露 | 定期报告 | 2024-09-04 |
| 2024-09-03 | 133.60 | 未披露 |
更多>>
Common Stock offered 347,277 shares by the company
|
2024-09-03 |
| 2024-08-14 | 98.88 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-07-25 | 92.63 | 未披露 |
更多>>
On July 24, 2024, the Company issued 25,000 shares of its common stock
|
2024-07-24 |
| 2024-07-12 | 90.13 | 未披露 |
更多>>
a reverse split of the Common Stock at a ratio of 1-for-10
|
2024-07-15 |
| 2024-07-12 | 901.25 | 未披露 | 定期报告 | 2024-07-12 |
| 2024-07-03 | 838.76 | 未披露 | 定期报告 | 2024-07-03 |
| 2024-05-06 | 757.34 | 1.64 |
更多>>
From December 31, 2023 to March 31, 2024
Conversion of Series A Convertible Preferred Stock
|
2024-03-31 |
| 2024-04-01 | 757.34 | 未披露 | 定期报告 | 2024-03-12 |
| 2024-04-01 | 702.66 | 1.72 |
更多>>
From December 31, 2022 to December 31, 2023
Common stock issued upon exercise of options
Warrants exercised net
Issuance of Series A Convertible Preferred Stock in connection with private placement, net
Restricted stock awards cancelled or vested
Conversion of Series A Convertible Preferred Stock
Conversion of Series X Convertible Preferred Stock
|
2023-12-31 |
| 2023-12-15 | 702.67 | 未披露 | 定期报告 | 2023-12-13 |
| 2023-12-21 | 700.80 | 1.73 |
更多>>
From June 30, 2023 to September 30, 2023
Conversion of Series A Convertible Preferred Stock
|
2023-09-30 |
| 2023-12-15 | 536.77 | 1.99 |
更多>>
From March 31, 2023 to June 30, 2023
Common stock issued upon the exercise of options
|
2023-06-30 |
| 2023-05-25 | 536.77 | 未披露 | 定期报告 | 2023-05-17 |
| 2023-04-21 | 536.77 | 未披露 | 定期报告 | 2023-04-19 |
| 2023-06-02 | 526.71 | 721.57 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of instruments in connection with private placement, net
Issuance of Series X preferred stock in merger
Conversion of Series X preferred stock
Common stock issued upon exercise of options
Restricted stock awards cancelled
Common stock issued upon exercise of warrants, net
|
2023-03-31 |
| 2023-03-28 | 498.41 | 未披露 | 定期报告 | 2023-03-23 |
| 2023-02-09 | 249.26 | 未披露 | 定期报告 | 2023-02-03 |
| 2023-02-01 | 282.45 | 未披露 | 定期报告 | 2023-01-30 |
| 2023-03-28 | 216.10 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Common stock issued, net
Warrants exercised
Restricted stock awards canceled
|
2022-12-31 |
| 2022-11-14 | 216.14 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-10-17 | 216.14 | 未披露 | 定期报告 | 2022-10-10 |
| 2022-09-20 | 109.03 | 未披露 |
更多>>
Ra Medical Systems, Inc. announces that its Board of Directors has approved a 1-for-50 reverse stock split of the Company’s common stock, with an effective time of 4:01 p.m. Eastern time on September 30, 2022.The Company’s common stock is expected to begin trading on a split-adjusted basis at commencement of trading on Monday, October 3, 2022.
|
2022-10-03 |
| 2022-09-15 | 7671.17 | 未披露 | 定期报告 | 2022-09-13 |
| 2022-08-29 | 5451.48 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-29 | 5290.92 | 未披露 | 定期报告 | 2022-07-22 |
| 2022-09-02 | 5432.75 | 未披露 | 定期报告 | 2022-07-05 |
| 2022-09-02 | 3227.89 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Common stock issued pursuant to the vesting of restricted stock units and purchases under the employee stock purchase plan
Restricted stock awards cancelled
|
2022-06-30 |
| 2022-05-16 | 3230.01 | 未披露 | 定期报告 | 2022-05-10 |
| 2022-04-21 | 3230.51 | 未披露 | 定期报告 | 2022-04-11 |
| 2022-05-16 | 3230.10 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Common stock and warrants issued, net
Warrants exercised
Restricted stock awards cancelled
|
2022-03-31 |
| 2022-03-24 | 3145.85 | 未披露 | 定期报告 | 2022-03-16 |
| 2022-02-08 | 1654.04 | 未披露 |
更多>>
1.Units offered by 9,535,000 units, each unit consisting of one share of common stock
2.Unless otherwise stated in this prospectus, the total number of shares of common stock outstanding as of the date of this prospectus and after this offering is based on 7,005,367 shares outstanding as of September 30, 2021
|
2022-02-08 |
| 2022-01-26 | 700.96 | 未披露 | 定期报告 | 2022-01-12 |
| 2022-03-24 | 701.00 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Common stock issued, net
Restricted stock awards cancelled
Common stock issued pursuant to the vesting of restricted stock units and purchases under employee stock purchase plan
|
2021-12-31 |
| 2021-11-15 | 702.98 | 未披露 | 定期报告 | 2021-11-10 |
| 2021-11-15 | 700.54 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Common stock issued, net
|
2021-09-30 |
| 2021-08-05 | 702.94 | 未披露 | 定期报告 | 2021-08-03 |
| 2021-08-11 | 590.26 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Common stock issued, net
Common stock issued pursuant to the vesting of restricted stock units and ESPP
Stock-based compensation
|
2021-06-30 |
| 2021-06-18 | 556.16 | 未披露 | 定期报告 | 2021-06-14 |
| 2021-05-17 | 509.16 | 未披露 | 定期报告 | 2021-05-14 |
| 2021-05-12 | 325.63 | 未披露 | 定期报告 | 2021-05-10 |
| 2021-04-26 | 325.60 | 未披露 | 定期报告 | 2021-04-09 |
| 2021-05-12 | 325.93 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Common stock issued, net
Stock-based compensation
|
2021-03-31 |
| 2021-03-17 | 325.93 | 未披露 | 定期报告 | 2021-03-10 |
| 2021-01-26 | 322.36 | 未披露 | 定期报告 | 2021-01-25 |
| 2021-03-17 | 318.87 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Common stock issued
Exercise of warrants
Common stock issued pursuant to the vesting of restricted stock units and ESPP
|
2020-12-31 |
| 2020-11-16 | 291.93 | 未披露 |
更多>>
Ra Medical Systems, Inc. (NYSE: RMED) announced today that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 16, 2020.
|
2020-11-17 |
| 2020-11-16 | 7298.21 | 未披露 | 定期报告 | 2020-11-11 |
| 2020-11-16 | 7246.83 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Common stock issued, net
|
2020-09-30 |
| 2020-08-11 | 7246.83 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-08-03 | 4818.11 | 未披露 |
更多>>
1.Units offered by the company 31,188,100 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
2.Unless otherwise stated in this prospectus, the total number of shares of common stock outstanding as of the date of this prospectus and after this offering is based on 13,895,349 shares outstanding as of March 31, 2020.
|
2020-08-03 |
| 2020-08-11 | 3818.26 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Common stock issued, net
Exercise of warrants
Common stock issued pursuant to the vesting of restricted stock units and ESPP
|
2020-06-30 |
| 2020-05-14 | 1389.53 | 未披露 |
更多>>
from December 31, 2019 to March 31, 2020
Common stock issued
|
2020-03-31 |
| 2020-03-11 | 1377.03 | 未披露 |
更多>>
from January 1, 2019 to December 31, 2019
Common stock issued
|
2019-12-31 |
| 2019-11-29 | 1340.80 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Common stock issued
|
2019-09-30 |
| 2019-11-29 | 1322.10 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Common stock issued
|
2019-06-30 |
| 2019-05-14 | 1292.88 | 未披露 | 定期报告 | 2019-05-10 |
| 2019-05-14 | 1283.70 | 未披露 |
更多>>
from January 1, 2019 to March 31, 2019
Common stock issued
|
2019-03-31 |
| 2019-03-15 | 1268.93 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Common stock issued, net of underwriters' discount of $5,338
|
2018-12-31 |
| 2018-11-14 | 1268.93 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-09-27 | 1210.43 | 未披露 |
更多>>
1.Common stock offered 3,900,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 8,204,251 shares of our common stock outstanding as of June 30, 2018
|
2018-09-27 |
| 2018-07-16 | 820.49 | 未披露 | 定期报告 | 2018-07-13 |
| 2018-08-24 | 820.43 | 未披露 | 定期报告 | 2018-06-30 |
a 1-for-10 reverse split ratio of common stock
From March 31, 2026 to June 30, 2026
Conversion of preferred stock
From December 31, 2025 to March 31, 2026
Conversion of preferred stock
Issuance of common stock and other equity-classified contracts
Issuance of common stock upon exercise of warrants
Common Stock offered 392,608 shares by the company
From December 31, 2024 to December 31, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock for asset acquisitions
Issuance of common stock upon release of Prepaid Series Warrants
Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs
Issuance of common stock upon the ATM Offering, net of issuance costs
Issuance of Series J Convertible Preferred Stock in exchange for royalties payable due to related parties, net of issuance costs
Conversion of convertible preferred stock
From June 30, 2025 to September 30, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock upon the ATM Offering, net of issuance costs
a 1-for-19 reverse split ratio of common stock
From March 31, 2025 to June 30, 2025
Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs
Conversion of preferred stock
Issuance of common stock upon the ATM Offering, net of issuance costs
Issuance of common stock upon release of Prepaid Series Warrants
Issuance of common stock for asset acquisition
Issuance of common stock for vested restricted stock awards
From December 31, 2024 to March 31, 2025
Issuance of common stock for vested restricted stock awards
Issuance of common stock for asset acquisition
Issuance of common stock upon release of Prepaid Series Warrants
From December 31, 2023 to December 31, 2024
Issuance of common stock upon exercise of Pre-Funded Warrants
Issuance of common stock upon exercise of Series Warrants
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs
Issuance of common stock through October 2024 Warrant Inducement Offer, net of issuance costs
Conversion of Series A Convertible Preferred Stock
From June 30, 2024 to September 30, 2024
Conversion of Series A Convertible Preferred Stock
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs
Issuance of common stock upon exercise of Pre-Funded Warrants
Common Stock offered 347,277 shares by the company
On July 24, 2024, the Company issued 25,000 shares of its common stock
a reverse split of the Common Stock at a ratio of 1-for-10
From December 31, 2023 to March 31, 2024
Conversion of Series A Convertible Preferred Stock
From December 31, 2022 to December 31, 2023
Common stock issued upon exercise of options
Warrants exercised net
Issuance of Series A Convertible Preferred Stock in connection with private placement, net
Restricted stock awards cancelled or vested
Conversion of Series A Convertible Preferred Stock
Conversion of Series X Convertible Preferred Stock
From June 30, 2023 to September 30, 2023
Conversion of Series A Convertible Preferred Stock
From March 31, 2023 to June 30, 2023
Common stock issued upon the exercise of options
From December 31, 2022 to March 31, 2023
Issuance of instruments in connection with private placement, net
Issuance of Series X preferred stock in merger
Conversion of Series X preferred stock
Common stock issued upon exercise of options
Restricted stock awards cancelled
Common stock issued upon exercise of warrants, net
From December 31, 2021 to December 31, 2022
Common stock issued, net
Warrants exercised
Restricted stock awards canceled
Ra Medical Systems, Inc. announces that its Board of Directors has approved a 1-for-50 reverse stock split of the Company’s common stock, with an effective time of 4:01 p.m. Eastern time on September 30, 2022.The Company’s common stock is expected to begin trading on a split-adjusted basis at commencement of trading on Monday, October 3, 2022.
From March 31, 2022 to June 30, 2022
Common stock issued pursuant to the vesting of restricted stock units and purchases under the employee stock purchase plan
Restricted stock awards cancelled
From December 31, 2021 to March 31, 2022
Common stock and warrants issued, net
Warrants exercised
Restricted stock awards cancelled
1.Units offered by 9,535,000 units, each unit consisting of one share of common stock
2.Unless otherwise stated in this prospectus, the total number of shares of common stock outstanding as of the date of this prospectus and after this offering is based on 7,005,367 shares outstanding as of September 30, 2021
From December 31, 2020 to December 31, 2021
Common stock issued, net
Restricted stock awards cancelled
Common stock issued pursuant to the vesting of restricted stock units and purchases under employee stock purchase plan
From June 30, 2021 to September 30, 2021
Common stock issued, net
From March 31, 2021 to June 30, 2021
Common stock issued, net
Common stock issued pursuant to the vesting of restricted stock units and ESPP
Stock-based compensation
From December 31, 2020 To March 31, 2021
Common stock issued, net
Stock-based compensation
from December 31, 2019 to December 31, 2020
Common stock issued
Exercise of warrants
Common stock issued pursuant to the vesting of restricted stock units and ESPP
Ra Medical Systems, Inc. (NYSE: RMED) announced today that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 16, 2020.
From June 30, 2020 to September 30, 2020
Common stock issued, net
1.Units offered by the company 31,188,100 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
2.Unless otherwise stated in this prospectus, the total number of shares of common stock outstanding as of the date of this prospectus and after this offering is based on 13,895,349 shares outstanding as of March 31, 2020.
from March 31, 2020 to June 30, 2020
Common stock issued, net
Exercise of warrants
Common stock issued pursuant to the vesting of restricted stock units and ESPP
from December 31, 2019 to March 31, 2020
Common stock issued
from January 1, 2019 to December 31, 2019
Common stock issued
from June 30, 2019 to September 30, 2019
Common stock issued
from March 31, 2019 to June 30, 2019
Common stock issued
from January 1, 2019 to March 31, 2019
Common stock issued
from December 31, 2017 to December 31, 2018
Common stock issued, net of underwriters' discount of $5,338
1.Common stock offered 3,900,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 8,204,251 shares of our common stock outstanding as of June 30, 2018